|
Different group
|
Perivascular eosinophilia
|
Peribronchiolar eosinophilia
|
Edema
|
Epithelial damage
|
|---|
|
OVA-1D-I
|
3(1–3)
|
1(1–2)
|
1(1–2)
|
1(1–3)
|
|
OVA-1D-N
|
3(2–3)
|
1(1–2)
|
1(1–2)
|
1(1–3)
|
|
OVA-3D-I
|
4(3–5)†
|
2.5(2–3)†
|
1(1–2)
|
2(1–3)
|
|
OVA-3D-N
|
3.5(3–5)†
|
2(2–3)†
|
1(1–2)
|
2(1–3)
|
|
Control(I)
|
0(0–0)*
|
0(0–0)*
|
0(0–0)*
|
0(0–1)*
|
- All mice were sensitized with OVA (10 ug, i.p) on days 0, 7 and 14. Mice in OVA-1D group were single-dose challenged on day 28. On day 29, responsiveness of mice was carried out with invasive measurements (OVA-1D-I group) or non-invasive measurements (OVA-1D-N group). Mice in OVA-3D group were three-dose challenged on day 28, 29, 30. On day 31, responsiveness of mice was carried out by invasive (OVA-3D-I group) or Penh measurements (OVA-3D-N group). The mice in Control (I) group were sensitized and challenged with normal saline.
- * P < 0.05 for Control group versus OVA immunized group, Kruskal-Wallis test.
-
†
P < 0.01 for OVA-3D group versus OVA-1D group, Kruskal-Wallis test.
